REACH Trial Evaluating First-Line Treatment of Refractory Chronic Cough Completes Enrollment

Top-line data anticipated in early Q3 2025.

BOSTON--(BUSINESS WIRE)--Sensory Cloud Inc., a health technology company pioneering treatments for respiratory illnesses of the airway lining, announced completion of enrollment of a Phase 2a trial (REACH* Study) evaluating SC0023, an alkaline hypertonic divalent salt (HDS) aerosol for the treatment of refractory chronic cough (RCC), afflicting an estimated 9 million Americans and currently without adequately safe and effective treatment options.

“I am excited by the REACH trial, which has been designed to clarify the potential of this new class of inhaled therapeutics as a first-line treatment for refractory chronic cough, which is presently lacking in current investigational drug programs advancing in clinical trials,” said Kian Fan Chung, MD, a co-investigator of the study and Professor of Respiratory Medicine and Head of Experimental Studies Medicine at the National Heart & Lung Institute, Imperial College London.

SC0023 is a proprietary HDS composition designed with ions and buffers endogenous to human airways to deactivate an upper-airway inflammatory cascade underlying cough hypersensitivity (1). David A. Edwards, PhD, founder, CEO and CSO of Sensory Cloud will share new clinical and scientific data on May 17 at the American Thoracic Society Meeting in San Francisco clarifying the antitussive (2) mode of action of SC0023 and its potential over the course of daily treatment to alleviate cough hypersensitivity aggravated by increasing atmospheric aridity (3).

An investigator-initiated trial at King Saud University Medical City, REACH is a randomized, double-blind, placebo-controlled crossover study evaluating the effect of SC0023 on cough frequency, relative to placebo, using a continuous digital cough monitor over 14 days per period. In addition, the study explores the daily progression of cough rate suppression over the course of treatment and post-treatment for up to three weeks, as well as patient-reported outcomes. The study, which is Institutional Review Board (IRB) approved and has been reviewed by the Saudi Food and Drug Administration (SFDA), is being led by principal investigators Kholood Altassan, MD, and Beshayr Alotaibi, MD, of King Saud University in the Kingdom of Saudi Arabia. Top-line results from the REACH trial are anticipated to be available in early Q3 2025.

*A Randomized, Double-Blind, Placebo Controlled Cross-Over Study to Investigate the Efficacy and Safety of SC0023, a Magnesium Salt Inhaled Therapeutic Aerosol, in Adults with Refractory or Unexplained Chronic Cough

About Sensory Cloud Inc.

Sensory Cloud Inc. is a Boston-based biotechnology company pioneering aerosols that rehydrate human upper airways for prophylaxis against and treatment of respiratory illnesses triggered by mucosal inflammation. The Company’s proprietary therapeutic platform, which deactivates mechano-sensitive channels to treat airway inflammation, is an outcome of 20 years of scientific research by founder David A. Edwards at Harvard University and Johns Hopkins University Medical School in collaboration with scientists and clinicians at other leading research institutions across the U.S. and internationally. Sensory Cloud Inc. is developing alkaline HDS therapies for treatment of chronic respiratory diseases of the upper airways. For further information, please contact [e-mail].

(1) Edwards DA, Chung KF. Mucus Transpiration as the Basis for Chronic Cough and Cough Hypersensitivity. Lung. 20, 17-24 (2024).

(2) Abubakar-Waziri H, Edwards DA, Bhatta DB, Hull JH, Rudd M, Small P, Chung KF. Inhaled alkaline hypertonic divalent salts reduce refractory chronic cough frequency. ERJ Open Res. 2024 Oct 7;10(5):00241-2024.

(3) Edwards DA, Edwards, A, Li, D Wang, L, Chung, KF, Bhatta, D, Bilstein, A Hanes,, Endirisinghe, I, Burton Freeman, B, Button, B. Global warming risks dehydrating and inflaming human airways. Nature Commun Earth Environ 6, 193 (2025)